Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BOLD
  • CUSIP: N/A
  • Web: www.audentestx.com
Capitalization:
  • Market Cap: $516.5 million
  • Outstanding Shares: 27,784,000
Average Prices:
  • 50 Day Moving Avg: $19.72
  • 200 Day Moving Avg: $16.90
  • 52 Week Range: $13.13 - $22.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.02
  • P/E Growth: -1.07
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.83 per share
  • Price / Book: 3.19
Profitability:
  • EBIDTA: ($73,430,000.00)
  • Return on Assets: -49.68%
Debt:
  • Current Ratio: 10.06%
  • Quick Ratio: 10.06%
Misc:
  • Average Volume: 135,977 shs.
  • Short Ratio: 6.41
 

Frequently Asked Questions for Audentes Therapeutics (NASDAQ:BOLD)

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics, Inc. (NASDAQ:BOLD) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by $0.10. View Audentes Therapeutics' Earnings History.

When will Audentes Therapeutics make its next earnings announcement?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Audentes Therapeutics.

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?

3 brokerages have issued 1-year price targets for Audentes Therapeutics' shares. Their predictions range from $20.00 to $24.00. On average, they anticipate Audentes Therapeutics' share price to reach $22.25 in the next year. View Analyst Ratings for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:

  • Matthew R. Patterson, President, Chief Executive Officer, Co-Founder, Director
  • Thomas J. Schuetz M.D. Ph.D., Co-Founder, Independent Director
  • Thomas P. Soloway, Chief Financial Officer, Senior Vice President
  • Natalie C. Holles, Chief Operating Officer, Senior Vice President
  • David Nagler, Senior Vice President - Human Resources and Corporate Affairs
  • John Gray Ph.D., Senior Vice President - Research and Development
  • Mary Newman, Senior Vice President - Regulatory Affairs
  • Suyash Prasad, Senior Vice President, Chief Medical Officer
  • Jennifer Jarrett, Director
  • Louis G. Lange M.D. Ph.D., Independent Director

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Audentes Therapeutics stock?

Audentes Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Versant Venture Management LLC (6.52%), Redmile Group LLC (6.67%), Jennison Associates LLC (3.05%), Vanguard Group Inc. (2.45%), Alliancebernstein L.P. (2.31%) and Franklin Resources Inc. (1.32%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, James E Flynn, Louis G Lange, Matthew R Patterson, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.

Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?

Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FMR LLC, Goldman Sachs Group Inc., Victory Capital Management Inc. and Citadel Advisors LLC. Company insiders that have sold Audentes Therapeutics stock in the last year include Louis G Lange and Matthew R Patterson. View Insider Buying and Selling for Audentes Therapeutics.

Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?

Audentes Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Jennison Associates LLC, Vanguard Group Inc., State Street Corp, Alliancebernstein L.P., Sphera Funds Management LTD., Northern Trust Corp and TIAA CREF Investment Management LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of Audentes Therapeutics stock can currently be purchased for approximately $18.59.


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.25 (19.69% upside)

Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$23.00LowView Rating Details
5/15/2017WedbushReiterated RatingOurperform$20.00LowView Rating Details
5/1/2017Leerink SwannInitiated CoverageOutperform$22.00LowView Rating Details
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Earnings History by Quarter for Audentes Therapeutics (NASDAQ BOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.88)N/AView Earnings Details
8/10/2017Q2 2017($0.77)($0.87)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
2017 EPS Consensus Estimate: ($3.32)
2018 EPS Consensus Estimate: ($3.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.93)($0.93)($0.93)
Q2 20172($0.84)($0.69)($0.77)
Q3 20172($0.86)($0.80)($0.83)
Q4 20172($0.87)($0.72)($0.80)
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.83)($0.83)($0.83)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Audentes Therapeutics (NASDAQ:BOLD)
Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 59.76%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2017Matthew R PattersonCEOSell15,000$20.00$300,000.00View SEC Filing  
7/12/2017Matthew R PattersonCEOSell2,850$20.00$57,000.00View SEC Filing  
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Audentes Therapeutics (NASDAQ:BOLD)
Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Anticipate Audentes Therapeutics, Inc. (BOLD) to Post -$0.82 EPS
www.americanbankingnews.com - August 18 at 8:12 AM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Now Covered by Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 14 at 6:38 PM
americanbankingnews.com logoLeerink Swann Comments on Audentes Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:BOLD)
www.americanbankingnews.com - August 14 at 3:36 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 14 at 2:44 AM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Posts Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - August 11 at 6:02 PM
finance.yahoo.com logoAudentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 5:49 PM
finance.yahoo.com logoAudentes Therapeutics reports 2Q loss
finance.yahoo.com - August 10 at 5:49 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - August 8 at 5:44 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - July 31 at 9:06 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - July 21 at 12:44 AM
americanbankingnews.com logoAudentes Therapeutics Inc (NASDAQ:BOLD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 12:28 AM
finance.yahoo.com logoAudentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
finance.yahoo.com - July 18 at 6:06 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 17 at 5:20 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) CEO Sells $57,000.00 in Stock
www.americanbankingnews.com - July 14 at 10:56 PM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) CEO Sells 15,000 Shares of Stock
www.americanbankingnews.com - July 14 at 10:56 PM
americanbankingnews.com logo-$0.79 Earnings Per Share Expected for Audentes Therapeutics, Inc. (BOLD) This Quarter
www.americanbankingnews.com - July 6 at 10:16 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Director Louis G. Lange Sells 15,000 Shares
www.americanbankingnews.com - June 28 at 7:40 PM
finance.yahoo.com logoAudentes Therapeutics Announces Participation in Upcoming Investor Conferences
finance.yahoo.com - June 28 at 4:42 PM
americanbankingnews.com logoBrokerages Expect Audentes Therapeutics, Inc. (BOLD) to Post ($0.79) Earnings Per Share
www.americanbankingnews.com - June 21 at 6:15 PM
finance.yahoo.com logoAudentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
finance.yahoo.com - June 13 at 1:00 PM
americanbankingnews.com logoZacks: Analysts Anticipate Audentes Therapeutics, Inc. (BOLD) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - June 12 at 10:22 PM
americanbankingnews.com logoBrokerages Expect Audentes Therapeutics Inc (BOLD) to Post ($0.76) EPS
www.americanbankingnews.com - June 2 at 12:30 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Short Interest Update
www.americanbankingnews.com - May 28 at 8:20 PM
finance.yahoo.com logoWhy Audentes Therapeutics (BOLD) Could Be Positioned for a Surge
finance.yahoo.com - May 19 at 3:56 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Audentes Therapeutics Inc Lifted by Analyst (BOLD)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 16 at 8:24 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Receives Ourperform Rating from Wedbush
www.americanbankingnews.com - May 15 at 9:34 PM
reuters.com logoBRIEF-Audentes Therapeutics qtrly loss per share $0.83
www.reuters.com - May 13 at 2:36 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:56 PM
finance.yahoo.com logoAudentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 9:14 AM
finance.yahoo.com logoAudentes Therapeutics reports 1Q loss
finance.yahoo.com - May 11 at 9:14 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 10 at 5:22 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 9 at 6:38 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Names John T. Gray, Ph.D. as SVP and Chief Scientific Officer
www.streetinsider.com - May 8 at 8:54 PM
finance.yahoo.com logoAudentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
finance.yahoo.com - May 8 at 10:26 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Expected to Post Q1 2017 Earnings of ($0.93) Per Share
www.americanbankingnews.com - May 4 at 8:04 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Announces Presentation of Data at ASGCT
www.streetinsider.com - May 4 at 2:04 AM
finance.yahoo.com logoAudentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
finance.yahoo.com - May 3 at 9:26 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - May 2 at 12:04 AM
americanbankingnews.com logoInsider Buying: Audentes Therapeutics Inc (BOLD) Insider Buys 172,413 Shares of Stock
www.americanbankingnews.com - April 26 at 10:52 PM
americanbankingnews.com logo-$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - April 25 at 5:18 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 24 at 4:42 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Prices 5.2M Share Offering at $14.50/Sh
www.streetinsider.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - April 19 at 1:12 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:57 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 17 at 12:26 PM
americanbankingnews.com logoZacks Investment Research Downgrades Audentes Therapeutics Inc (BOLD) to Sell
www.americanbankingnews.com - April 11 at 4:34 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:37 PM

Social

Chart

Audentes Therapeutics (BOLD) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff